DELAFIELD, WI – Gold In September® (G9) has announced the addition of Shelly Schumacher to their organization. Schumacher will serve as the non-profit’s Public Relations and Marketing Director.
Most recently Schumacher was the owner of her own marketing and communications consultancy, servicing the communication needs of small to medium sized businesses. She brings a broad range of professional capabilities to G9 including agency experience, market research and a solide background writing for the print and digital media.
“We are excited have Shelly join the G9 team,” notes Sarah Bartosz, President of G9. “She brings a broad depth of knowledge in Marcom that will help us take our communications program to the next level,” she adds.
For her part, Schumacher is looking forward to helping advance the G9 mission, using her professional skills as well as a passion to make a difference. “I am at a point in my career where I have enjoyed many professional successes. I was looking for a career move that would not only allow me to use my marketing and PR expertise, but also make a difference. Taking on this role at G9 will allow me to do just that. I look forward to helping build the G9 brand and spreading the message of our important mission so that every child, everywhere will survive cancer,” Schumacher says.
About Gold In September® (G9) G9 is a childhood cancer non-profit dedicated to increasing funding for childhood cancer research and initiatives by growing awareness that inspires action to help every child, everywhere. G9 directly funds Early Phase Trials, bringing the newest, most promising treatments to kids faster. Utilizing a noble model of turning the world gold to raise awareness and meet the mission, G9 directly benefits the entire childhood cancer community with gold alliance, resulting in increased funding and support for all childhood cancer initiatives. For more information about Gold In September® visit www.goldinseptember.com.
Mind if we hang out
in your inbox?
We only email once or twice a month, always relevant to how we're working to beat neuroblastoma and other childhood cancers.
Thank you for subscribing!
Something went wrong.